News | Pfizer | Pfizer

Home

News

Zinc Finger Transcription Factors: The On/Off Switch for Genes Inspired by Frogs

Zinc finger transcription technology could be the on/off switch for mutated genes, opening the door to improved ALS treatment.

Science

Making the COVID-19 Oral Treatment: How 2,000+ Pfizer Team Members Made It Happen

As the potential threat of COVID-19 became clear by early 2020, teams across Pfizer sprang into action. Together, they worked to better understand the novel virus.

Our Purpose

Net Zero by 2040: How Pfizer is Fighting Climate Change with Ambitious Science Based Goals

In 2015, on the eve of the Paris Agreement, Pfizer was one of the first companies in the world to seek and gain approval of its greenhouse gas emission reduction goal.

Carbon Neutral by 2030: How Pfizer is Fighting Climate Change with Ambitious Science Based Goals

Search More Stories

Behind the Science Features

Experience multimedia stories that give you an exciting view of Pfizer’s initiatives as we pursue breakthroughs that change patients’ lives.

Go Behind the Science

Media Resources

This information is intended for media professionals. To ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.

Pipeline Snapshot as of July 28, 2022

00Phase 1
00Phase 2
00Phase 3
00Registration
00Total

Download Complete Pipeline PDF

Clinical Trials

We proudly partner with thousands of study sites and tens of thousands of trial participants around the world. It’s these clinical trials that lead to life-changing medicines.

Go to Pfizer Clinical Trials Site

Our Careers

Incredible things can happen when people come together with one shared goal. The future of medicine is happening at Pfizer, and we’re eager to work alongside inspired and inspirational people who want to improve healthcare around the world.

Explore Our Careers

To Our Investors

Our ambitions are big and our product pipeline has never been stronger. We’re energized and inspired to apply science and our global resources to develop and deliver breakthrough therapies to people everywhere.

To Our Investors

Why Invest

Financial Reports

Events and Presentations

Stock Information

Investor News

Investor Insights

Shareholder Services

Stay Informed. Knowledge is Power.

Zinc Finger Transcription Factors: The On/Off Switch for Genes Inspired by Frogs

Making the COVID-19 Oral Treatment: How 2,000+ Pfizer Team Members Made It Happen

Net Zero by 2040: How Pfizer is Fighting Climate Change with Ambitious Science Based Goals

Experience multimedia stories that give you an exciting view of Pfizer’s initiatives as we pursue breakthroughs that change patients’ lives.

September 2022

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive for COVID-19

Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A Has Re-Opened Recruitment

Pfizer Declares Fourth-Quarter 2022 Dividend

Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries

Pfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts

CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development

Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union

Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in the European Union

Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents

Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022

Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine

We proudly partner with thousands of study sites and tens of thousands of trial participants around the world. It’s these clinical trials that lead to life-changing medicines.

Incredible things can happen when people come together with one shared goal. The future of medicine is happening at Pfizer, and we’re eager to work alongside inspired and inspirational people who want to improve healthcare around the world.

Our ambitions are big and our product pipeline has never been stronger. We’re energized and inspired to apply science and our global resources to develop and deliver breakthrough therapies to people everywhere.

Stay Informed. Knowledge is Power.

Experience multimedia stories that give you an exciting view of Pfizer’s initiatives as we pursue breakthroughs that change patients’ lives.

Year

Month

September 2022

We proudly partner with thousands of study sites and tens of thousands of trial participants around the world. It’s these clinical trials that lead to life-changing medicines.

Incredible things can happen when people come together with one shared goal. The future of medicine is happening at Pfizer, and we’re eager to work alongside inspired and inspirational people who want to improve healthcare around the world.

Our ambitions are big and our product pipeline has never been stronger. We’re energized and inspired to apply science and our global resources to develop and deliver breakthrough therapies to people everywhere.